Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Travere Therapeutics (TVTX – Research Report) and Insmed (INSM – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Travere Therapeutics (TVTX)
In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics, with a price target of $47.00. The company’s shares closed last Friday at $30.39.
According to TipRanks.com, Nash is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Travere Therapeutics with a $42.73 average price target, implying a 44.9% upside from current levels. In a report issued on February 20, TipRanks – Google also upgraded the stock to Buy with a $33.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Insmed (INSM)
In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Insmed, with a price target of $204.00. The company’s shares closed last Monday at $163.59.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $217.29 average price target, representing a 35.0% upside. In a report issued on February 16, Roth MKM also maintained a Buy rating on the stock with a $212.00 price target.
